The less a postmenopausal woman moves, the higher her risk of mortality, according to a new study in the American Journal of Preventive Medicine.
The less a postmenopausal woman moves, the higher her risk of mortality, according to a new study in the American Journal of Preventive Medicine.
Researchers from Cornell University looked at the 92,234 women aged 50 to 79 years who had participated in the Women’s Health Initiative Observational Study through September 2010. The women self-reported the amount of sedentary time via a questionnaire and were then sorted into 4 categories (≤4, >4-8, ≥8-11, >11 hours). The average follow-up period was 12 years.
Study: Even a little exercise is better than none for overweight postmenopausal women
Women who reported the highest sedentary time had an increased risk of all-cause mortality when compared to women with the least amount of sedentary time (hazard ratio [HR] = 1.12, 95% confidence interval [CI] = 1.05, 1.21). When separated into cause of mortality (cardiovascular disease [HR 1.13, 95% CI= 0.99, 1.29], coronary heart disease [HR= 1.27, 95% CI = 1.04, 1.55], and cancer [HR=1.21, 95% CI= 1.07, 1.37]), women who reported the least amount of physical activity were at increased risk compared with women with the highest level of activity.
The investigators concluded that the more time a woman spent sitting would linearly increase her mortality risks. They said that women should start taking precautions such as taking breaks from the computer or getting up during television commercials, as early as possible.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More